MerLion Pharmaceuticals Pte Ltd and Cancer Research Technology Announce Drug Discovery Collaboration

21-Sep-2005

MerLion Pharmaceuticals Pte Ltd and Cancer Research Technology Ltd (CRT) have entered into a large-scale screening programme to identify new anti-cancer drug candidates derived from natural product chemistry.

Within the collaboration MerLion will screen their natural compound collection against high throughput screens developed by scientists at CRT in order to isolate new therapeutic compounds against validated cancer targets. Targets will be selected from research carried out by Cancer Research UK and CRT's other academic partners.

Following the identification of lead compounds, it is anticipated that the expertise in medicinal chemistry both at MerLion and CRT will be utilised to perform compound optimisation. The companies will work in close partnership throughout the target selection and screening process. The results of the collaboration will be jointly owned.

This international partnership follows the Joint Statement on Science, Engineering and Technology signed by Prime Ministers Lee Hsien Loong and Tony Blair on 4th July 2005, building on the UK-Singapore Partners in Science initiative.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

A*STAR Joins Forces with Cytos to Combat Hand, Foot and Mouth Disease

CMC Biologics Announce Appointment of David Wolton as VP Manufacturing

Revotar announces promising results suggesting COPD as a potential target for selectin antagonist treatment in humans

GPC Biotech AG Named in Purported Class Action Lawsuit in the United States

Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board

Currently positioned only 5th, China is the fastest growing biotech market in the world

BGU researchers make scientific breakthrough in the fight against neurodegenerative diseases - BGN Technologies secures funding of over $1m. to develop patented treatment

Pivotal phase IIIa trials for Organon's novel oral contraceptive, NOMAC/E2, complete recruitment

Gene Logic Expands GeneExpress Product Line, Launches GeneExpress Women's Health DataSuite - New Product Enables Analysis of Distinctions in Female and Male/ Female Gene Expression

Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine - IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer